Published in Mol Cell Biol on August 01, 2001
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev (2010) 2.97
Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther (2007) 2.80
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc Natl Acad Sci U S A (2002) 2.79
Targeted disruption of murine organic anion-transporting polypeptide 1b2 (Oatp1b2/Slco1b2) significantly alters disposition of prototypical drug substrates pravastatin and rifampin. Mol Pharmacol (2008) 2.11
Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc Natl Acad Sci U S A (2003) 2.03
The SLC22 drug transporter family. Pflugers Arch (2003) 1.95
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies. Br J Pharmacol (2012) 1.74
Deficiency in the organic cation transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in mice abolishes renal secretion of organic cations. Mol Cell Biol (2003) 1.45
Muscarinic receptors and ligands in cancer. Am J Physiol Cell Physiol (2008) 1.42
What do drug transporters really do? Nat Rev Drug Discov (2014) 1.41
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J Clin Invest (2007) 1.41
Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes (2009) 1.34
Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes (2014) 1.29
OCT1 is a high-capacity thiamine transporter that regulates hepatic steatosis and is a target of metformin. Proc Natl Acad Sci U S A (2014) 1.24
Functional characterization of liver enhancers that regulate drug-associated transporters. Clin Pharmacol Ther (2011) 1.14
Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx (2005) 1.11
Drug transporters, the blood-testis barrier, and spermatogenesis. J Endocrinol (2010) 1.05
Drug-drug interaction studies: regulatory guidance and an industry perspective. AAPS J (2013) 1.04
Organic cation transporter 1 (OCT1/mOct1) is localized in the apical membrane of Caco-2 cell monolayers and enterocytes. Mol Pharmacol (2013) 1.03
Influence of Oct1/Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin Cancer Res (2010) 1.01
Regulation of organic cation transport. Pflugers Arch (2004) 0.98
Metformin Is a Substrate and Inhibitor of the Human Thiamine Transporter, THTR-2 (SLC19A3). Mol Pharm (2015) 0.96
Organic cation transporter OCTs (SLC22) and MATEs (SLC47) in the human kidney. AAPS J (2013) 0.95
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene. J Pharmacol Exp Ther (2013) 0.91
Targeted disruption of organic cation transporter 3 attenuates the pharmacologic response to metformin. Mol Pharmacol (2015) 0.89
Drug-metabolizing enzyme, transporter, and nuclear receptor genetically modified mouse models. Drug Metab Rev (2010) 0.88
The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol Sin (2009) 0.87
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia. Int J Mol Sci (2015) 0.86
Organic anion and cation SLC22 "drug" transporter (Oat1, Oat3, and Oct1) regulation during development and maturation of the kidney proximal tubule. PLoS One (2012) 0.84
Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1). Clin Cancer Res (2013) 0.82
Pharmacogenetics: potential role in the treatment of diabetes and obesity. Expert Opin Pharmacother (2008) 0.82
Activation of the extraneuronal monoamine transporter (EMT) from rat expressed in 293 cells. Br J Pharmacol (2002) 0.82
Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm Res (2010) 0.81
Atorvastatin induces bile acid-synthetic enzyme Cyp7a1 by suppressing FXR signaling in both liver and intestine in mice. J Lipid Res (2014) 0.80
Prediction and validation of enzyme and transporter off-targets for metformin. J Pharmacokinet Pharmacodyn (2015) 0.80
Organic anion transporter 3 inhibitors as potential novel antihypertensives. Pharmacol Res (2008) 0.79
Assessment of the Relation between the Expression of Oxaliplatin Transporters in Colorectal Cancer and Response to FOLFOX-4 Adjuvant Chemotherapy: A Case Control Study. PLoS One (2016) 0.78
Global genetic analyses reveal strong inter-ethnic variability in the loss of activity of the organic cation transporter OCT1. Genome Med (2015) 0.75
A critical role of solute carrier 22a14 in sperm motility and male fertility in mice. Sci Rep (2016) 0.75
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 4.76
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 1.77
Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med (1980) 1.62
Immuno-localization of H+/peptide cotransporter in rat digestive tract. Biochem Biophys Res Commun (1996) 1.61
cDNA sequence, transport function, and genomic organization of human OCTN2, a new member of the organic cation transporter family. Biochem Biophys Res Commun (1998) 1.59
Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem (1998) 1.59
Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett (1997) 1.50
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol (1996) 1.45
Organic cation transporters in intestine, kidney, liver, and brain. Annu Rev Physiol (1998) 1.44
Transport of monoamine transmitters by the organic cation transporter type 2, OCT2. J Biol Chem (1998) 1.31
Functional characteristics and membrane localization of rat multispecific organic cation transporters, OCT1 and OCT2, mediating tubular secretion of cationic drugs. J Pharmacol Exp Ther (1998) 1.29
Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol (2000) 1.29
cDNA cloning and functional expression of a novel rat kidney organic cation transporter, OCT2. Biochem Biophys Res Commun (1996) 1.18
Comparison of the sodium dependency of uptake of meta-lodobenzylguanidine and norepinephrine into cultured bovine adrenomedullary cells. Mol Pharmacol (1984) 1.15
Functional characterization of an organic cation transporter (hOCT1) in a transiently transfected human cell line (HeLa). J Pharmacol Exp Ther (1998) 1.11
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem (1996) 1.08
Catecholamine transport by the organic cation transporter type 1 (OCT1). Br J Pharmacol (1998) 1.08
The Lx1 gene maps to mouse chromosome 17 and codes for a protein that is homologous to glucose and polyspecific transmembrane transporters. Mamm Genome (1996) 1.03
Evaluation of metaiodobenzylguanidine uptake by the norepinephrine, dopamine and serotonin transporters. J Nucl Med (1993) 1.02
Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem Biophys Res Commun (1998) 0.99
Role of blood-brain barrier P-glycoprotein in limiting brain accumulation and sedative side-effects of asimadoline, a peripherally acting analgaesic drug. Br J Pharmacol (1999) 0.96
Molecular and functional characteristics of cloned human organic cation transporters. Pharm Biotechnol (1999) 0.94
Uptake mechanisms of meta-[123I]iodobenzylguanidine in isolated rat heart. Nucl Med Biol (1995) 0.93
A reevaluation of substrate specificity of the rat cation transporter rOCT1. J Biol Chem (1997) 0.92
Transport of small organic cations in the rat liver. The role of the organic cation transporter OCT1. Naunyn Schmiedebergs Arch Pharmacol (1997) 0.91
Functional expression of a high affinity mammalian hepatic choline/organic cation transporter. J Lipid Res (2000) 0.88
Renal secretion of purine nucleosides and their analogs in mice. Biochem Pharmacol (1983) 0.83
Sequestration of organic cations by acidified hepatic endocytic vesicles and implications for biliary excretion. J Pharmacol Exp Ther (1992) 0.83
131I-MIBG therapy of neural crest tumours (review). Anticancer Res (1997) 0.83
Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance. Nucl Med Commun (1995) 0.82
The biodisposition of MPP+ in mouse brain. Neurosci Lett (1989) 0.81
The metabolism of [14C]cimetidine in man. Xenobiotica (1982) 0.79
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell (1994) 6.02
Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell (1993) 4.76
Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res (2001) 4.05
The Drosophila homolog of the mouse mammary oncogene int-1 is identical to the segment polarity gene wingless. Cell (1987) 3.78
P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest (1996) 3.75
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A (1997) 3.20
Cloning and expression of a rat brain L-glutamate transporter. Nature (1992) 3.14
Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest (1995) 3.13
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci U S A (1997) 2.91
MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell (1996) 2.87
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst (2000) 2.73
Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol (1994) 2.26
Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci (2001) 2.19
The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther (2009) 2.19
Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS (2000) 1.96
Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin Pharmacol Ther (2009) 1.94
Wnt-3, a gene activated by proviral insertion in mouse mammary tumors, is homologous to int-1/Wnt-1 and is normally expressed in mouse embryos and adult brain. Proc Natl Acad Sci U S A (1990) 1.94
Activation of the genes for variant surface glycoproteins 117 and 118 in Trypanosoma brucei. J Mol Biol (1983) 1.91
Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol (1997) 1.91
Bidirectional action of the Igf2r imprint control element on upstream and downstream imprinted genes. Genes Dev (2001) 1.89
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. Proc Natl Acad Sci U S A (2000) 1.83
The antiperinuclear factor. 1. The diagnostic significance of the antiperinuclear factor for rheumatoid arthritis. Ann Rheum Dis (1979) 1.81
The human multidrug resistance-associated protein functionally complements the yeast cadmium resistance factor 1. Proc Natl Acad Sci U S A (1996) 1.78
Drug excretion mediated by a new prototype of polyspecific transporter. Nature (1994) 1.77
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin. Cancer Res (1999) 1.76
Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med (1997) 1.75
Specificity factor of yeast mitochondrial RNA polymerase. Purification and interaction with core RNA polymerase. J Biol Chem (1987) 1.70
Tissue distribution of the human MDR3 P-glycoprotein. Lab Invest (1994) 1.69
Transfection of the int-1 mammary oncogene in cuboidal RAC mammary cell line results in morphological transformation and tumorigenicity. EMBO J (1987) 1.69
Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest (1998) 1.65
P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A (1996) 1.65
Acquisition of proviral DNA of mouse mammary tumor virus in thymic leukemia cells from GR mice. J Virol (1982) 1.53
Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833. J Clin Invest (1997) 1.48
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol (1996) 1.45
Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant (2000) 1.42
Rearrangements in the long terminal repeat of extra mouse mammary tumor proviruses in T-cell leukemias of mouse strain GR result in a novel enhancer-like structure. Mol Cell Biol (1985) 1.41
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2013) 1.40
Regulation of biliary lipid secretion by mdr2 P-glycoprotein in the mouse. J Clin Invest (1995) 1.39
CD34+/CD36- cells from myelodysplasia patients have a limited capacity to proliferate but can differentiate in response to Epo and MGF stimulation. Leukemia (1998) 1.39
Basolateral localization and export activity of the human multidrug resistance-associated protein in polarized pig kidney cells. J Clin Invest (1996) 1.37
Impaired activity of the extraneuronal monoamine transporter system known as uptake-2 in Orct3/Slc22a3-deficient mice. Mol Cell Biol (2001) 1.37
Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. Diabetologia (2012) 1.35
The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett (1994) 1.34
Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. J Clin Invest (2000) 1.32
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol (2001) 1.30
Localization of organic cation transporters OCT1 and OCT2 in rat kidney. Am J Physiol Renal Physiol (2000) 1.29
Activation of int-1 and int-2 mammary oncogenes in hormone-dependent and -independent mammary tumors of GR mice. J Virol (1987) 1.29
Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol (1998) 1.28
N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein. J Biol Chem (1993) 1.28
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J Pharmacol Exp Ther (2006) 1.27
Stable transformation of Trypanosoma brucei. Mol Biochem Parasitol (1993) 1.25
Extensive contribution of the multidrug transporters P-glycoprotein and Mrp1 to basal drug resistance. Cancer Res (2000) 1.25
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst (1996) 1.21
Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest (1999) 1.21
Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine. Mol Pharmacol (1998) 1.21
Specific detection of multidrug resistance proteins MRP1, MRP2, MRP3, MRP5, and MDR3 P-glycoprotein with a panel of monoclonal antibodies. Cancer Res (2000) 1.20
Cloning of a membrane-associated protein which modifies activity and properties of the Na(+)-D-glucose cotransporter. J Biol Chem (1993) 1.19
Mitochondrial RNA polymerase: dual role in transcription and replication. Trends Genet (1989) 1.17
Reaction of monoclonal antibodies with plasma membrane proteins after binding on nitrocellulose: renaturation of antigenic sites and reduction of nonspecific antibody binding. Anal Biochem (1987) 1.16
Site-specific rearrangements in the long terminal repeat of extra mouse mammary tumor proviruses in murine T-cell leukemias. Virology (1986) 1.15
The position of short and long loops of Henle in the rat kidney. Z Anat Entwicklungsgesch (1972) 1.15
Drug uptake systems in liver and kidney. Curr Drug Metab (2003) 1.14
Non-invasive cardiac imaging techniques and vascular tools for the assessment of cardiovascular disease in type 2 diabetes mellitus. Diabetologia (2008) 1.11
(R)- and (S)-[11C]verapamil as PET-tracers for measuring P-glycoprotein function: in vitro and in vivo evaluation. Nucl Med Biol (2003) 1.11
Multidrug resistance and the role of P-glycoprotein knockout mice. Eur J Cancer (1995) 1.10
The structural organization of the mouse kidney. Z Anat Entwicklungsgesch (1974) 1.10
Expression of the Na+-D-glucose cotransporter SGLT1 in neurons. J Neurochem (1997) 1.09
Successful chemotherapy with deoxycoformycin in adult T-cell lymphoma-leukaemia. Br J Haematol (1984) 1.09
Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther (1993) 1.08
Electrogenic properties and substrate specificity of the polyspecific rat cation transporter rOCT1. J Biol Chem (1996) 1.08
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833. Br J Cancer (1997) 1.06
Health effects of therapeutic use of 131I in hyperthyroidism. Q J Nucl Med (2000) 1.06
Binding properties of monoclonal antibodies recognizing external epitopes of the human MDR1 P-glycoprotein. Int J Cancer (1993) 1.04
Altered expression of hepatic cytochromes P-450 in mice deficient in one or more mdr1 genes. Mol Pharmacol (2000) 1.04
Reconstitution and partial purification of several Na+ cotransport systems from renal brush-border membranes. Properties of the L-glutamate transporter in proteoliposomes. J Biol Chem (1984) 1.03
Transport of the new chemotherapeutic agent beta-D-glucosylisophosphoramide mustard (D-19575) into tumor cells is mediated by the Na+-D-glucose cotransporter SAAT1. Proc Natl Acad Sci U S A (1998) 1.03
The Wnt-1 (int-1) oncogene promoter and its mechanism of activation by insertion of proviral DNA of the mouse mammary tumor virus. Mol Cell Biol (1990) 1.01
Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci (2000) 1.01
Impact of the exon 3-deleted growth hormone (GH) receptor polymorphism on baseline height and the growth response to recombinant human GH therapy in GH-deficient (GHD) and non-GHD children with short stature: a systematic review and meta-analysis. J Clin Endocrinol Metab (2009) 1.01
What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer (1996) 1.00
ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain (2009) 0.99